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Screening for HBsAg, HCV and HIV among pregnant women,  
Istria County, 2011-2012 
 
Testiranje trudnica na biljege virusnog hepatitisa B i C te HIV infekcije u  
Istarskoj županiji tijekom 2011. i 2012. godine 
 






During a two year period (2011 - 2012), a total of 1,596 consecutive serum samples from pregnant 
women were tested for the presence of HBsAg, anti-HCV and anti-HIV antibodies. HBsAg was detected in 
11/1596 (0.7%; 95% CI = 0.34 - 1.23) tested women. All of them were HBeAg negative/anti-HBe positive. 
According to age, HBsAg prevalence was highest in the age group of less than 26 years (1.9%). In the age 
groups 26-30 and 31-35 years, prevalence rates of 0.5% and 0.4% were found. Differences among age 
groups were not significant (p = 0.096). Comparing age groups, a significantly lower prevalence of HBsAg 
was found in 31 - 35 age group compared to the youngest age group (< 26 years) (OR = 0.19, 95%                       
CI = 0.04-0.97). Anti-HCV antibodies were detected in 12/960 tested women (1.3%, 95% CI = 0.64-2.17). 
HCV seropositivity increased significantly with age from 0.3% to 3.1% beginning with the 26-30 age group 
(p = 0.03). Place of residence was not associated with HBsAg (0.8% in urban areas vs. 0% in rural areas,                
p = 0.616) or anti-HCV positivity (1.8% in urban vs. 1.2% in rural areas, p = 0.641). None of the 1,002 
participants were HIV positive. The results of this study suggest that Croatia is a low-prevalence country for 
HBV, HCV and HIV infection.   




Tijekom dvogodišnjega razdoblja (2011. – 2012. godine), testirano je ukupno 1596 uzoraka seruma 
trudnica na prisutnost HBsAg, anti-HCV i anti-HIV protutijela. HBsAg je dokazan u 11/1596 (0,7%; 95%CI 
= 0,34 - 1,23) testiranih žena. S obzirom na dob, prevalencija HBsAg bila je najviša (1,9%) u skupini mlađih 
od 26 godina.U dobi od 26-30 i 31-35 godina bilo je pozitivno 0,5%, odnosno 0,4% ispitanica. Razlike 
između dobnih skupina nisu bile statistički značajne (p = 0,096). Uspoređujući dobne skupine, nađena je 
značajno niža prevalencija HBsAg u skupini od 31 - 35 godina u usporedbi s najmlađom dobnom skupinom 
(< 26 godina) (OR = 0,19; 95%CI = 0,04 - 0,97). Anti-HCV protutijela nađena su u 12/960 testiranih žena 
(1,3%; 95%CI = 0,64 - 2,17). Opažen je značajan porast HCV seropozitiviteta s dobi od 0,3% do 3,1%, 
počevši s dobnom skupinom od 26-30 godina (p = 0,03). Ovisno o mjestu prebivališta (urbano ili ruralno 
područje), nije bilo značajne razlike u prevalenciji HBsAg (0.8% u urbanoj te 0% u ruralnoj sredini;                  
p = 0,616) niti anti-HCV (1,8% u urbanoj, te 1,2% u ruralnoj sredini; p = 0,641). Niti jedna ispitanica nije 
bila HIV pozitivna. Rezultati ovoga istraživanja ukazuju na nisku prevalenciju HBV, HCV i HIV infekcije u 
Hrvatskoj.  
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Hepatitis B virus (HBV) and hepatitis C virus 
(HCV) infections represent an important public health 
problem worldwide.
1
 Vertical transmission from 
infected mother to child is a common route of HBV 
transmission. It is widely accepted that most perinatal 
transmission of HBV occurs at or near the time of 
birth, because neonatal vaccination prevents newborn 
infection in about 80% - 95% of cases.
2
 The risk of 
perinatal HBV transmission is reported to be 70 - 
90% for infants born to mothers who are 
HBsAg/HBeAg positive, and it decreases to 5 - 20% 
for infants born to HBsAg/anti-HBe positive 
mothers.
3
 Worldwide, 30 - 50% of chronic HBV 
infections could be attributed to maternal-infant 
transmission.
4
 Since perinatal transmission of HBV 
results in a high frequency of chronic infection (up to 
90%), early recognition of HBsAg positive pregnant 
women helps in identifying newborns at risk of 




The acquisition of HCV infection through 
perinatal transmission is estimated to occur in about 1 
- 6% of infants born to HCV-infected mothers, with 
the risk being proportional with the level of the 
mother’s viremia.
6
 Moreover, most studies have 
reported a higher risk of perinatal HCV transmission 
in infants born to HIV co-infected mothers.
7,8
 Since 
there is no effective method for preventing vertical 
HCV transmission, routine prenatal screening for 
HCV infection is not currently advised. However, 
screening of high-risk women is important because 
antiviral therapy could be considered in the 
postpartum period that may decrease their risk of end 
stage liver disease and hepatocellular carcinoma.
9
 
More than 90% of HIV infections in children are 
caused by perinatal transmission.
10
 The risk of perinatal 
HIV could be reduced from 15 - 40% to less than 2% 
if an accurate diagnosis of the mother’s HIV infection 
is made and appropriate treatment provided.
11,12
 
Seroprevalence of HBV, HCV and HIV differs 
among countries as well as among different regions 
and populations in the same country. The aim of this 
study was to evaluate the prevalence of HBsAg, anti-
HCV and anti-HIV among pregnant women in Istria 
County, Croatia. 
 
Materials and methods 
 
The study area was Istria County, the largest 
Croatian peninsula located in the north-western part 
of the Adriatic Sea. Istria County has in total 208,055 
inhabitants with about 1,400 deliveries per year. 
During a two-year period (2011 - 2012), a total of 
1,596 consecutive serum samples from pregnant 
women aged 18-47 years (Picture 1) attending 
antenatal polyclinics were tested for the presence of 
HBsAg, anti-HCV and anti-HIV antibodies. HBsAg 
testing of pregnant women is mandatory, while anti-
HCV and anti-HIV tests were performed on the 
request of the referring physician. HBsAg was 
detected using commercial enzyme-linked fluorescent 
assay (ELFA). Repeatedly reactive samples were 
further analyzed using confirmation test with 
neutralizing antibodies (Mini Vidas, bioMérieux, 
Marcy l'Etoile, France). HBsAg positive samples 
were additionally tested for the presence of HBeAg, 
anti-HBe, anti-HBs, anti-HBc total antibodies and 





Picture 1 Age distribution of study participants 
Slika 1. Raspodjela učesnika studije prema dobi 
 
Anti-HCV antibodies were screened by third 
generation enzyme-linked immunoassay (Ortho HCV 
Version 3.0 ELISA Test, Ortho-Clinical Diagnostics, 
Raritan, NY, USA). Initially reactive samples were 
confirmed by third generation line immunoassay 
(INNO-LIA HCV Score, Innogenetics, Ghent, 
Belgium). 
HIV screening was performed by commercial 
ELISA for detection of HIV1/HIV2 IgG antibodies 
(HIV 1&2 Ab, Dialab GmbH, Neudorf, Austria). 
Borderline reactive samples would have been tested 
by fourth generation ELFA with simultaneous 
detection of p24 Ag; HIV1/HIV2 IgG antibodies 
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Statistical analysis  
 
Differences between groups of variables were 
assessed using Fisher’s exact test for categorical 
variables and Mann-Whitney U test for continuous 
variables. The strength of association between outputs 
(HBsAg, anti-HCV) was assessed using binary 
logistic regression. The software used for this analysis 




HBsAg was detected in 11/1596 (0.7%; 95% CI = 
0.34-1.23) tested pregnant women. All HBsAg 
carriers were positive for anti-HBc total antibodies 
and anti-HBe while anti-HBs and IgM anti-HBc 
antibodies were negative. According to age, HBsAg 
prevalence varied from 0.4% to 1.9% with no 
significant difference between age groups (p = 0.096) 
(Table 1). There was no seropositive woman above 
36 years of age. Comparing seroprevalence by age 
groups using the youngest age group as a reference 
group, a significantly lower seroprevalence was 
found in 31-35 age group compared to the youngest 
age group (< 26 years) (OR = 0.19, 95% CI = 0.04-
0.97). The median age of HBsAg positive women 
was significantly lower than the median age of 
HBsAg negative women (25 vs. 30 years, p = 0.007) 
(Table 3). 
Anti-HCV antibodies were detected in 12/960 
tested pregnant women (1.3%, 95% CI=0.64-2.17). A 
significant increase in anti-HCV positivity with age 
was observed from 0.3% to 3.1% beginning with the 
26-30 age group (p = 0.03). There was no HCV 
seropositivity detected in women younger than 25 and 
older than 40 years of age (Table 2).  
 
Table 1  Prevalence of HBsAg in pregnant women, Istria County, Croatia 
Tablica 1. Učestalost HBsAg kod trudnica, Istarska županija, Hrvatska  
Characteristics  Tested /testirane HBsAg positive / pozitivno 
Karakteristike  N (%)   N (%)  95% CI     OR 95% CI (OR) 
Age group (years) / Dobne skupine 
       < 26  309 (19.4)  6 (1.9)  0.71-4.18 1 N/A* 
     26-30  546 (34.2)  3 (0.5)  0.11-1.60 0.28 0.07 - 1.12 
     31-35  520 (32.6)  2 (0.4)  0.05-1.38 0.19 0.04 - 0.97 
     36-40  194 (12.1)  0  N/A -1.88 N/A N/A 
     40+       27 (1.7)  0  N/A -12.77 N/A N/A 
Place of residence/ Mjesto boravka          
Rural / ruralno    161 (10.1)  0  N/A -2.27 N/A N/A 
Urban / urbano  1435 (89.9)  11 (0.8)  0.38-1.37 N/A N/A 
*N/A = not applicable / ne primjenjuje se 
 
Table 2   Prevalence of anti-HCV antibodies in pregnant women, Istria County, Croatia 
Tablica 2.  Učestalost anti-HCV antitijela kod trudnica, Istarska županija, Hrvatska  
 
Characteristics  Tested / testirane anti-HCV positive / pozitivno  
Karakteristike  N (%)   N (%)  95% CI      OR 95% CI (OR) 
Age group (years) / Dobne skupine  
       < 26  167 (17.4)  0  N/A*- 2.18    
     26-30  322 (33.5)  1 (0.3)  0.01-1.7 ** 1 N/A 
     31-35  332 (34.6)  7 (2.1)  0.85-4.29 6.91 0.85-56.51 
     36-40  127 (13.2)  4 (3.1)  0.86-7.87 10.44 1.16-94.32 
     40+       12 (1.3)  0  N/A -26.46 N/A N/A 
Place of residence / Mjesto boravka         
Rural / ruralno  112 (11.7)  2 (1.8)  0.22-6.3 1 N/A 
Urban / urbano  848 (88.3)  10 (1.2)  0.57-2.16 0.66 0.14-3.03 
*N/A = not applicable/ ne primjenjuje se      ** p = 0.030 
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The median age of anti-HCV positive women was 
significantly higher than the median age of anti-HCV 
negative women (34 vs. 30 years, p = 0.003) (Table 3). 
The place of residence was not associated with 
HBsAg (0.8% in urban areas vs. 0% in rural areas, p 
= 0.616) or anti-HCV positivity (1.8% in urban vs. 
1.2% in rural areas, p = 0.641) (Table 1 and 2). 
None of the 1,002 tested participants were anti-HIV 
borderline or positive. 
 
Table 3  Median age of HBsAg positive/negative and 
anti-HCV positive/negative participants 
Tablice 3. Prosječna dob HBsAg negativne/pozitivne 
te anti-HCV pozitivne/negativne učesnice 
 
Serologic markers   Median age (years) p 
Serološki markeri   Proječna dob  
HBsAg               0.007 
     Positive / Pozitivno    25 (18 - 33) 
     Negative /Negativno   30 (18 - 47) 
Anti-HCV              0.003 
     Positive / Pozitivno   34 (29 - 40) 





The overall HBsAg prevalence found in Istria 
County (0.7%) is comparable to that reported in 
France (0.65%)
13
 and in Gijón, Spain (0.8%).
14
 In 
some European countries lower prevalences were 
reported: 0.1% in Norway,
15
 0.1% in Catalonia, 
Spain,
16
 0.26% - 0.4% in Denmark
17,18
 and 0.48% in 
Germany.
19





 and Greece (2.9%-
3.9%)
22,23
 and very high in Albania (7.3%).
24
 There 
are few data on the HBsAg prevalence among 
pregnant women in Croatia. Two studies conducted in 
1995 and 1999 showed seropositivity of 1% in the 
Istria and Rijeka regions
25
 and 0.75% in Dalmatia.
26
 
In 2011, the overall HBsAg prevalence based on 
information from 31 maternity hospitals was 0.2%, 
with a range from 0.0% to 1.3%. The prevalence of 
HBsAg in women giving birth in Pula Maternity 
Hospital (Istria County) was 0.5% (data from the 
CNIPH). The difference in HBsAg seroprevalence in 
pregnant women in Istria County found in this study 
and the one reported by Pula Maternity Hospital for 
2011 indicates that the populations are different. 
Namely, all women who were tested for HBsAg in 
our study did not necessarily give birth in Pula 
hospital and women who come to give birth in Pula 
could have been tested elsewhere (private laboratories 
or public health laboratories in other counties). In the 
future, we can expect a further decrease in HBsAg 
prevalence among pregnant women, since universal 
hepatitis B immunization of 12-year olds was intro-
duced in 1999 and consequently, the pool of suscep-
tible young adults is decreasing. 
Until 1990, intrafamiliar transmission and IDU 
were the main risk factors for HBV infection. In most 
recent years, risk sexual behaviour, in particular 
multiple sexual partners, has been predominant.
20
 
From among 11 HBsAg positive pregnant women in 
this study, two were household contacts of HBsAg 
carriers, two had multiple hospitalizations with 
surgical procedures, one had pierced her ears in 
childhood, one had a history of blood transfusion in 
1992 and one had sexual contacts with a promiscuous 
partner. The remaining four women did not report any 
identifiable risk factor for HBV infection. 
As in France, where the highest HBsAg positivity 
was observed in pregnant women before the age of 
20,
13
 the highest percentage of positive women in our 
study was recorded before the age of 26 (1.9%). This 
group includes the women who should have been 
vaccinated against HBV and we expected lower 
HBsAg positivity. However, four participants (out of 
six positive in this group) in the youngest age group 
belong to the Roma ethnic group, in which the 
vaccination program is not implemented regularly and 
completely. Three of them had uncontrolled preg-
nancies.  
There are very few data on the prevalence of HCV 
in pregnant women in Croatia. In this study, we found 
the overall anti-HCV prevalence of 1.3%, which is 
similar to that reported from Gijón, Spain (1.44%).
14
 
In Europe, lower prevalences were reported in the 
United Kingdom (0.19%-0.22%)
27
 and Scotland 
(0.3%-0.4%).
28
 Italy, Greece and Slovakia reported 




In a previous Croatian study (2003-2006), lower 
prevalence of HCV among pregnant women (0.5%) 
was found than in our study.
31
 Injection risk behavior 
is considered to be the predominant mode of HCV 
infection.
32
 In Croatia, the overall prevalence of HCV 
among intravenous drug users (IDUs) is reported to 
be 51%.
33,34
 A similar prevalence of HCV (49%) was 
found among pregnant IDUs.
35
 Of 12 anti-HCV 
positive pregnant women in this study, 10 reported a 
history of IDU while one reported a former 
relationship with an IDU. Like British authors,
27
 we 
found a significant increase in HCV seropositivity 
with age.  
In this study, we found no HIV seropositive women 
which reflects the very low prevalence of HIV 
infection in the Croatian general population (< 0.1%).
36
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The limitation of this study is a sample size, which 
resulted in relatively wide confidence intervals, which 
should be taken into account at interpretation of the 
results. Seroprevalence studies in some other 
population groups such as occupationally exposed 
groups would shed more light to understanding the 
epidemiology of these infections, in addition to 
already studied prevalence in high-risk groups. 
In conclusion, the results of this study seem to 
confirm observations from earlier studies and routine 
data collection which indicate that Croatia is a 
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